Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

• Main Authors: Pamela L. St Jean, Zhengyu Xue, Nick Carter, Gavin C.K.W. Koh, Stephan Duparc, Maxine Taylor, Claire Beaumont, Alejandro Llanos-Cuentas, Ronnatrai Rueangweerayut, Srivicha Krudsood, Justin A. Green, Justin P. Rubio
• Other Authors: PAREXEL International
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/40844
• Institution: Mahidol University

© 2016 St Jean et al. Background: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection and TQ is currently in phase 3 clinical trials for the sam...